Scopus Biopharma Inc. Financials
This page shows Scopus Biopharma Inc. (SCPS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2022 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Scopus Biopharma Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Scopus Biopharma Inc. carries a low D/E ratio of -1.06, meaning only $-1.06 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 81/100, indicating a strong balance sheet with room for future borrowing.
Key Financial Metrics
Earnings & Revenue
Scopus Biopharma Inc. generated $0 in revenue in fiscal year 2022.
Scopus Biopharma Inc. earned $-0.55 per diluted share (EPS) in fiscal year 2022. This represents an increase of 64.7% from the prior year.
Cash & Balance Sheet
Scopus Biopharma Inc. held $125K in cash against $0 in long-term debt as of fiscal year 2022.
Scopus Biopharma Inc. had 21M shares outstanding in fiscal year 2022. This represents an increase of 0.0% from the prior year.
Margins & Returns
Capital Allocation
Scopus Biopharma Inc. invested $2K in capex in fiscal year 2022, funding long-term assets and infrastructure. This represents a decrease of 22.4% from the prior year.
SCPS Income Statement
| Metric | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | N/A | $0 | $0 | $0 | N/A | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $2.0M+23.9% | $1.6M | N/A | $917K+41.2% | $649K+76.0% | $369K | N/A | $78K |
| SG&A Expenses | $936K-12.6% | $1.1M | N/A | $981K-63.2% | $2.7M-37.8% | $4.3M | N/A | $2.7M |
| Operating Income | N/A | N/A | N/A | -$1.9M+42.8% | -$3.3M+28.8% | -$4.7M | N/A | -$2.8M |
| Interest Expense | N/A | N/A | N/A | $0 | $0 | $0 | N/A | $111K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$2.4M | N/A | -$1.9M+42.8% | -$3.3M+28.8% | -$4.7M | N/A | -$1.4M |
| EPS (Diluted) | $-0.07+12.5% | $-0.08 | N/A | $-0.09+43.8% | $-0.16+27.3% | $-0.22 | N/A | $-0.08 |
SCPS Balance Sheet
| Metric | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $498K-69.0% | $1.6M+308.7% | $392K-5.6% | $416K-75.2% | $1.7M-63.7% | $4.6M-43.7% | $8.2M+103.1% | $4.0M |
| Current Assets | $496K-69.0% | $1.6M+310.6% | $390K-5.6% | $413K-75.3% | $1.7M-63.7% | $4.6M-43.7% | $8.2M+103.2% | $4.0M |
| Cash & Equivalents | $362K-74.2% | $1.4M+1025.0% | $125K-59.9% | $311K-73.1% | $1.2M-70.9% | $4.0M-50.0% | $7.9M+118.7% | $3.6M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $9.9M+16.4% | $8.6M+22.9% | $7.0M+17.5% | $5.9M+10.2% | $5.4M+4.5% | $5.1M+23.2% | $4.2M+86.4% | $2.2M |
| Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | $4.2M+86.4% | $2.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$9.5M-36.1% | -$6.9M-5.8% | -$6.6M-19.3% | -$5.5M-48.8% | -$3.7M-597.2% | -$530K-113.2% | $4.0M+123.9% | $1.8M |
| Retained Earnings | -$58.1M-4.7% | -$55.5M-4.6% | -$53.1M-3.4% | -$51.3M-3.8% | -$49.4M-7.2% | -$46.1M-11.2% | -$41.5M-18.7% | -$34.9M |
SCPS Cash Flow Statement
| Metric | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.0M-32.8% | -$760K-80.1% | -$422K+50.5% | -$852K+70.4% | -$2.9M+27.7% | -$4.0M+4.1% | -$4.1M-64.8% | -$2.5M |
| Capital Expenditures | N/A | N/A | $0 | $0 | $0-100.0% | $2K | $0-100.0% | $2K |
| Free Cash Flow | N/A | N/A | -$422K+50.5% | -$852K+70.4% | -$2.9M+27.7% | -$4.0M+4.1% | -$4.1M-64.7% | -$2.5M |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | -$45K-102.2% | $2.0M+734.7% | $242K | $0 | $0 | $0-100.0% | $8.5M+8214.6% | -$105K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SCPS Financial Ratios
| Metric | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -78.0% |
| Return on Assets | N/A | -152.8% | N/A | -456.8%-258.3pp | -198.4%-97.3pp | -101.2% | N/A | -34.7% |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | 1.96+0.2 | 1.80 |
| Debt-to-Equity | -1.05+0.2 | -1.23-0.2 | -1.06+0.0 | -1.08+0.4 | -1.45+8.2 | -9.69-10.7 | 1.04-0.2 | 1.25 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$6.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
What is Scopus Biopharma Inc.'s annual revenue?
Scopus Biopharma Inc. (SCPS) reported $0 in total revenue for fiscal year 2022. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
What are Scopus Biopharma Inc.'s total assets?
Scopus Biopharma Inc. (SCPS) had $392K in total assets as of fiscal year 2022, including both current and long-term assets.
What are Scopus Biopharma Inc.'s capital expenditures?
Scopus Biopharma Inc. (SCPS) invested $2K in capital expenditures during fiscal year 2022, funding long-term assets and infrastructure.
What is Scopus Biopharma Inc.'s debt-to-equity ratio?
Scopus Biopharma Inc. (SCPS) had a debt-to-equity ratio of -1.06 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.
Why is Scopus Biopharma Inc.'s debt-to-equity ratio negative or unusual?
Scopus Biopharma Inc. (SCPS) has negative shareholder equity of -$6.6M as of fiscal year 2022, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
How financially healthy is Scopus Biopharma Inc.?
Scopus Biopharma Inc. (SCPS) scores 19 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.